Overview

Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma

Status:
RECRUITING

Trial end date:
2029-09-25

Target enrollment:

Participant gender:

Summary

A prospective, randomized, open-label, multicenter Phase 2 trial designed to compare the efficacy and safety of Tislelizumab combined with chemotherapy followed by surgery versus up-front surgery in resectable clinically node-negative head and neck squamous cell carcinoma.

Phase:

PHASE2

Details

Lead Sponsor:

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Treatments:

Radiation